Self-report data as a tool for subtype identification in genetically-defined Parkinson’s Disease
暂无分享,去创建一个
N. Eriksson | A. Winslow | J. Wilk | C. Hyde | W. Hirst | P. Cannon | Melissa R. Miller
[1] M. Leite,et al. Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease , 2017, Journal of the Neurological Sciences.
[2] M. Nalls,et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.
[3] E. Tolosa,et al. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non‐Ashkenazi Jewish ancestry , 2017, Movement disorders : official journal of the Movement Disorder Society.
[4] Donal N. Gorman,et al. GWAS of self-reported mosquito bite size, itch intensity and attractiveness to mosquitoes implicates immune-related predisposition loci , 2017, Human molecular genetics.
[5] G. Rouleau,et al. LRRK2 mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. , 2015, Parkinsonism & related disorders.
[6] K. Marder,et al. Differential effects of severe vs mild GBA mutations on Parkinson disease , 2015, Neurology.
[7] Chuong B. Do,et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.
[8] M. Rudzińska,et al. Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients. , 2014, Neurologia i neurochirurgia polska.
[9] P. Mazzoni,et al. Parkinson disease phenotype in Ashkenazi jews with and without LRRK2 G2019S mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[10] Nir Giladi,et al. Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation , 2013, Movement disorders : official journal of the Movement Disorder Society.
[11] K. Marder,et al. Cognitive performance of GBA mutation carriers with early-onset PD , 2012, Neurology.
[12] P. Pollak,et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers , 2012, Neurology.
[13] Nicholas Eriksson,et al. Novel Associations for Hypothyroidism Include Known Autoimmune Risk Loci , 2011, PloS one.
[14] Nicholas Eriksson,et al. Web-Based Genome-Wide Association Study Identifies Two Novel Loci and a Substantial Genetic Component for Parkinson's Disease , 2011, PLoS genetics.
[15] Jeffrey M. Hausdorff,et al. Gait alterations in healthy carriers of the LRRK2 G2019S mutation , 2011, Annals of neurology.
[16] Brian T. Naughton,et al. Web-Based, Participant-Driven Studies Yield Novel Genetic Associations for Common Traits , 2010, PLoS genetics.
[17] K. Marder,et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. , 2009, Archives of neurology.
[18] M. Nalls,et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.
[19] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[20] K. Marder,et al. Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease , 2007, Neurology.
[21] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[22] M. Farrer,et al. LRRK2 mutations in Parkinson disease , 2005, Neurology.
[23] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[24] M. Burns,et al. Case-Control Study , 2020, Definitions.
[25] R. Schiffmann,et al. Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? , 2003, Molecular genetics and metabolism.
[26] Nir Giladi,et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. , 1996, QJM : monthly journal of the Association of Physicians.
[27] E. Sidransky,et al. Glucocerebrosidase mutations in subjects with parkinsonism. , 2004, Molecular genetics and metabolism.
[28] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .